Firefly Neuroscience, Inc. — SEC Form D Filing

Firefly Neuroscience, Inc. filed an SEC Form D on March 13, 2026, reporting $2.25M raised in Health Technology.

Form D filing details

Filing
SEC Form D
Filing date
March 13, 2026
Amount reported
$2.25M
Round stage
Seed
Industry
Health Technology
Website
https://fireflyneuro.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Neurological and psychiatric healthcare often lacks objective measurements, making it difficult to deliver consistent and evidence-based care.

Solution

Firefly Neuroscience offers the Brain Network Analytics (BNA™), an AI-driven system that provides objective assessments of brain health using EEG data, enabling better diagnosis and management of cognitive disorders.

Verdict

Investors decided to support Firefly Neuroscience at this moment largely because the promise of objective measurements in neurological care offered a compelling narrative, not because the technology itself was proven. This implicates a bet on the increasing demand for data-driven approaches in an industry traditionally reliant on subjective assessments, but the limited upside lies in potential competition from established healthcare technologies and the inherent challenges of clinical adoption.

Source: SEC EDGAR Form D filing